Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List On Positive Phase 3 Results

(MENAFN- Investor Ideas) Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Dermata Therapeutics, Inc. (Nasdaq: DRMA , DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications.

Dermata today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARITM, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.

The stock makes the NASDAQ top gainers list in today's trading , currently at$ 1.6802, up 0.3302. gaining 24.4484% on volume of over 63 Million shares . The stock has a day's high of $2.37.

The XYNGARITM Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARITM.

"I believe having a once-weekly topical product with a strong efficacy and safety profile, like XYNGARITM, would be a great addition to a dermatologist's arsenal for treating acne," commented Dr. Sunil Dhawan, MD, FAAD, FACP, clinical investigator at the Center for Dermatology Clinical Research, Inc., a participating site in the STAR-1 trial. "All FDA approved topical acne products are required to be applied at least once or twice a day, which may reduce patient compliance, so I believe having a once-weekly topical acne product like XYNGARITM could lead to improved patient compliance," concluded Dr. Dhawan.

"We are incredibly excited about these Phase 3 clinical trial results for XYNGARITM, which we believe reinforce its potential as a unique acne treatment, distinct from any existing product on the market," said Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata. "The highly statistically significant efficacy data not only confirms the results of our Phase 2b acne study but also strengthens our confidence about the upcoming XYNGARITM Phase 3 STAR-2 trial, set to launch in the second half of 2025. With these positive Phase 3 clinical trial results, we are eager to advance discussions with potential partners interested in securing future rights to XYNGARITM," Mr. Proehl added.

Full news

Biotech stocks to watch:

Research more Biotech and medical technology stocks with Investorideas free stock directory

About Investorideas - Big Investing Ideas

Investorideas is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

Disclaimer/Disclosure: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:

Global investors must adhere to regulations of each country.

MENAFN28032025000142011025ID1109369045